Press Release
Transient expression of proteins from mammalian cells reach higher than 1 gram/liter yields
ExcellGene scientists accomplished an important breakthrough in recombinant antibody production based on transient gene expression (TGE) in mammalian cells in collaboration with the Laboratory of Cellular Biotechnology at the Swiss Federal Institute of Technology in Lausanne Switzerland (EPFL). A scientific paper describing aspects of the established technology has been published in the highly recognized scientific journal Nucleic Acids Research.
Most current production methods in mammalian cells involve the time- and labor-consuming step of establishing stable cell lines. TGE is a novel concept for manufacturing of recombinant proteins. With TGE, it is not required to generate a stable cell line, but DNA encoding the protein of interest is directly used as an ingredient in the manufacturing process. This allows for fast production of recombinant proteins (from gene to gram and kilogram quantities of proteins within weeks instead of months). ExcellGene scientists succeeded in overcoming the major bottlenecks of transient gene expression in terms of low specific productivity and titers by multi-parameter vector and process optimization. With ExcellGene's new, patented TGExpress platform, specific productivity of 20 to 30 pg per cell per day and volumetric titers of more than 1 g/l can be obtained with transient gene expression. ExcellGene offers multiple services along the value chain to its customers based on its TGExpress platform- In combination with its TubeSpin satellite technology, ExcellGene offers high-throughput small-scale antibody lead production (10 to 20 mg). Here, hundreds of antibodies can be produced in parallel per month.
- Based on its Orbital Shake Bioreactor platform (1L to 1,000L scale), ExcellGene offers fast and reliable contract manufacturing of recombinant proteins using its TGExpress technology. ExcellGene customers can order grams of recombinant protein for preclinical studies to be delivered in weeks instead of months.
Building further on its strength in transient gene expression and orbital shaking bioreactors at the 1,000L scale, ExcellGene is in the process of establishing a GMP facility to further meet the needs of its customers. For further information about ExcellGene's services, please contact Dr. J. A. Balta at +41 24 471 9660, antonio.balta@excellgene.com
